數位生物標記：開啟疾病管理和藥物研發的新視角

本報告深入探討了製藥業，並全面分析了數位生物標記在藥物研究、藥物研發和疾病管理中不斷演變的作用。基於對頂尖專家的深入訪談，報告探討了穿戴式裝置、生物感測器和人工智慧驅動分析技術的進步如何實現持續、客觀、以患者為中心的數據，從而增強臨床試驗和真實世界證據的生成。

主要的問題

• 1. 數位生物標記如何開啟藥物研發與疾病管理的新視野？
• 2. 製藥公司如何利用數位生物標記來促進臨床研發？
• 3. 驗證和鑑定數位生物標記在臨床應用中的關鍵挑戰是什麼？
• 4. 有哪些成功應用數位生物標記推進藥物研發專案的案例？
• 5. 數位生物標記如何支持疾病管理和病患照護？
• 6. 數位生物標記在製藥業的應用和採用的最新趨勢是什麼？
• 7. 生物製藥公司未來有哪些機會可以利用數位生物標記來改善治療結果？
• 8. 數位生物標記如何支持創新藥物的報銷？
• 9. 確保數位生物標記符合用途的關鍵考慮因素是什麼？
• 10. 製藥公司如何合作和投資以推進其數位生物標記策略？

主要企業

This report delivers a comprehensive analysis of the evolving role of digital biomarkers in pharmaceutical research, drug development and disease management. Based on in-depth interviews with leading experts, it explores how advances in wearable devices, biosensors and AI-driven analytics are enabling continuous, objective and patient-centric data to enhance clinical trials and real-world evidence generation.

The report explores the integration of digital endpoints into clinical development, the regulatory frameworks and validation challenges shaping their use, and the impact of digital biomarkers on patient monitoring, compliance and personalised medicine. It also considers collaborative strategies, emerging therapeutic use cases and the future trends influencing adoption across the biopharma landscape. Gain actionable insights into the opportunities and challenges of implementing digital biomarker strategies to support more efficient, data-driven and value-based healthcare.

Key Questions Answered:

• 1. How are digital biomarkers unlocking new insights in drug development and disease management?
• 2. In what ways are pharmaceutical companies using digital biomarkers to enhance clinical development?
• 3. What are the main challenges in validating and qualifying digital biomarkers for clinical use?
• 4. Where have digital biomarkers been successfully deployed to drive drug development programs?
• 5. How are digital biomarkers supporting disease management and patient care?
• 6. What are the latest trends in the adoption and application of digital biomarkers in pharma?
• 7. What future opportunities exist for biopharma to leverage digital biomarkers for improved outcomes?
• 8. How can digital biomarkers support the reimbursement of innovative medicines?
• 9. What are the key considerations for ensuring digital biomarkers are fit-for-purpose?
• 10. How are pharma companies collaborating and investing to advance digital biomarker strategies?

Key Companies:

Partial List of Participating Experts:

• Vice President, Clinical Outcome Assessment Program, Critical Path Institute, US
• Vice President, Critical Path Institute, US
• Executive Scientific Director, Research & Strategy, Modus Outcomes, US
• Science Director, VivoSense, Switzerland
• Vice President of Data Science, Mitra bio, UK
• Scientific Director, Tecniplast, Germany

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.